ADEL develops therapeutics targeting central nervous system disorders and advances antibody candidates through clinical development. Its notable programs include ADEL-Y01, a tau antibody candidate that was licensed out to Sanofi in a deal valued up to $1.04 billion with an $80 million non-refundable upfront payment. The company is advancing follow-on candidates ADEL-Y04 (ApoE4-targeting antibody) and ADEL-Y03 (β2-microglobulin-targeting antibody) and aims to accelerate their clinical timelines. ADEL intends to strengthen partnerships with domestic and international CNS specialists and further develop proprietary technology platforms. The company cites global business achievements and investor support as validation of its pipeline value. Management plans to complete a KOSDAQ technology special listing within the year and deploy the newly secured funds to deliver early pipeline development results.

Total raised

$46M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2026